Skip to main content
. 2020 Oct 2;11:516211. doi: 10.3389/fneur.2020.516211

Table 4.

Therapeutic strategy among the three groups.

Groups MuSK-MG AChR-MG DSN-MG
Pyridostigmine bromide 8/14 (57.1%) 130/130 (100%) 39/39 (100%)
Glucocorticoid 14/14 (100%) 94/130 (72.3%) 16/39 (33.3%)
Immunosuppressant 13/14 (92.9%) 86/130 (66.2%) 1/39 (2.6%)
Intravenous immunoglobulin 6/14 (42.9%) 37/130 (28.5%) 5/39 (12.8%)
Plasma exchange 2/130 (1.6%)